Research Topics
| Rami KantorSummaryAffiliation: Brown University Country: USA Publications
| Collaborators
|
Detail Information
Publications
Impact of HIV-1 pol diversity on drug resistance and its clinical implicationsRami Kantor
Division of Infectious Diseases, The Miriam Hospital, Providence, Rhode Island 02906, USA
Curr Opin Infect Dis 19:594-606. 2006..This review summarizes publications from the past year relevant to the impact of HIV diversity on drug resistance evolution and its potential clinical implications...
Misclassification of first-line antiretroviral treatment failure based on immunological monitoring of HIV infection in resource-limited settingsRami Kantor
Division of Infectious Diseases, Brown University, Providence, Rhode Island, USA
Clin Infect Dis 49:454-62. 2009..The early identification of first-line antiretroviral treatment failure is critical to prevent morbidity, mortality, and drug resistance. Misclassification of failure may result in premature switching to second-line therapy...
Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: results of a global collaborationRami Kantor
Division of Infectious Disease and Center for AIDS Research, Stanford University, Stanford, California, USA
PLoS Med 2:e112. 2005..The genetic differences among HIV-1 subtypes may be critical to clinical management and drug resistance surveillance as antiretroviral treatment is expanded to regions of the world where diverse non-subtype-B viruses predominate...- Mutation patterns and structural correlates in human immunodeficiency virus type 1 protease following different protease inhibitor treatmentsThomas D Wu
Department of Biochemistry, Stanford University, Stanford, California 94305, USA
J Virol 77:4836-47. 2003..The presence of mutational clusters provides insight into the complex mutational patterns required for HIV-1 protease inhibitor resistance... - HIV-1 pol mutation frequency by subtype and treatment experience: extension of the HIVseq program to seven non-B subtypesSoo Yon Rhee
Division of Infectious Disease, Stanford University, Stanford, California, USA
AIDS 20:643-51. 2006..As additional non-B sequences from persons with well-characterized antiretroviral treatment histories have become available, the program has been extended to subtypes A, C, D, F, G, CRF01, and CRF02... - Drug resistance in plasma and breast milk after single-dose nevirapine in subtype C HIV type 1: population and clonal sequence analysisSeble Kassaye
Department of Medicine and Infectious Diseases, Stanford University, Stanford, California 94305, USA
AIDS Res Hum Retroviruses 23:1055-61. 2007..Population sequencing underestimates the diversity of NNRTI resistance mutations within minority populations following SD NVP in subtype C HIV-1 viral RNA in plasma and breast milk... - Envelope coreceptor tropism, drug resistance, and viral evolution among subtype C HIV-1-infected individuals receiving nonsuppressive antiretroviral therapySeble Kassaye
Department of Medicine, Division of Infectious Diseases, Stanford University Medical Center, Stanford, CA 94305, USA
J Acquir Immune Defic Syndr 50:9-18. 2009..In resource-constrained settings, antiretroviral treatment (ART) is often continued based on clinical and CD4 responses, without virologic monitoring. ART with incomplete viral suppression was assessed in 27 subjects with subtype C HIV-1... - Drug resistance in non-subtype B HIV-1Rami Kantor
Division of Infectious Diseases, Center for AIDS Research, Stanford University Medical Center, 300 Pasteur Drive, room S 156, Stanford, CA 94305, USA
J Clin Virol 29:152-9. 2004..Here we review HIV diversity and the published literature on drug resistance, comparing the known resistance mutations in individuals infected with subtype B to the growing experience in the treatment of non-subtype B HIV-1 worldwide... - HIV-1 subtype C reverse transcriptase and protease genotypes in Zimbabwean patients failing antiretroviral therapyRami Kantor
Division of Infectious Diseases and AIDS Research, Stanford University, California 94305, USA
AIDS Res Hum Retroviruses 18:1407-13. 2002..Comparison of subtype C RT and protease sequences with a large database of subtype B sequences identified subtype C-specific polymorphisms and candidate drug resistance mutations... - Extended spectrum of HIV-1 reverse transcriptase mutations in patients receiving multiple nucleoside analog inhibitorsMatthew J Gonzales
Division of Infectious Diseases, Department of Medicine, Stanford University, CA, USA
AIDS 17:791-9. 2003..Most NRTI mutations group into one of three clusters, although several (e.g., M184V) occur in multiple mutational contexts... - Breast-milk shedding of drug-resistant HIV-1 subtype C in women exposed to single-dose nevirapineEsther J Lee
Center for AIDS Research, Division of Infectious Disease, Stanford University School of Medicine, Stanford, CA 94305, USA
J Infect Dis 192:1260-4. 2005..In 20 paired BM and plasma samples, 65% of BM and 50% of plasma RT sequences had NNRTI-resistance mutations, with divergent mutation patterns... - Evolution of resistance to drugs in HIV-1-infected patients failing antiretroviral therapyRami Kantor
Division of Infectious Diseases, Center for AIDS Research, Stanford University, Stanford, California, USA
AIDS 18:1503-11. 2004..The frequency with which new drug-resistance mutations (DRM) developed and their potential consequences in patients continuing unchanged treatment despite persistent viremia were assessed... - Human immunodeficiency virus reverse transcriptase and protease sequence databaseSoo-Yon Rhee
Division of Infectious Diseases, Department of Medicine, Stanford University, Stanford, CA 94305, USA
Nucleic Acids Res 31:298-303. 2003..Sequence data on two new molecular targets of HIV drug therapy--gp41 (cell fusion) and integrase--will be added to the database in 2003... - Polymorphism in HIV-1 non-subtype B protease and reverse transcriptase and its potential impact on drug susceptibility and drug resistance evolutionRami Kantor
Division of Infectious Diseases and AIDS Research, Stanford University, Stanford, CA, USA
AIDS Rev 5:25-35. 2003.... - High frequency of syncytium-inducing and CXCR4-tropic viruses among human immunodeficiency virus type 1 subtype C-infected patients receiving antiretroviral treatmentElizabeth R Johnston
Division of Infectious Diseases and AIDS Research, Stanford University, Stanford, California 94035, USA
J Virol 77:7682-8. 2003..These results suggest that CXCR4-tropic viruses are present within the quasispecies of patients infected with subtype C virus and that antiretroviral treatment may create an environment for the emergence of CXCR4 tropism... - The HIV-1 Non-subtype B Workgroup: an international collaboration for the collection and analysis of HIV-1 non-subtype B dataRami Kantor
Division of Infectious Diseases, Brown University, Providence, Rhode Island, USA
MedGenMed 7:71. 2005 - Short communication: Transmitted drug resistance and molecular epidemiology in antiretroviral naive HIV type 1-infected patients in Rhode IslandPhilip A Chan
Division of Infectious Disease, The Warren Alpert Medical School of Brown University, Providence, Rhode Island, USA
AIDS Res Hum Retroviruses 27:275-81. 2011..Molecular epidemiological analysis and association of resistance with phylogenetic networks using data obtained for clinical purposes may serve as useful tools for the prevention of drug resistance transmission and for contact tracing... - Prediction of treatment failure using 2010 World Health Organization Guidelines is associated with high misclassification rates and drug resistance among HIV-infected Cambodian childrenBenjamin P Westley
Division of Infectious Diseases, Alpert Medical School, Brown University, Providence, Rhode Island, USA
Clin Infect Dis 55:432-40. 2012..Revised WHO pediatric guidelines were published in 2010, but their ability to accurately identify virological failure is unclear... - Sequence quality analysis tool for HIV type 1 protease and reverse transcriptaseAllison K Delong
Center for Statistical Sciences, Brown University, Providence, Rhode Island 02906, USA
AIDS Res Hum Retroviruses 28:894-901. 2012.... - Low prevalence of transmitted K65R and other tenofovir resistance mutations across different HIV-1 subtypes: implications for pre-exposure prophylaxisPhilip A Chan
Division of Infectious Diseases, The Warren Alpert Medical School of Brown University, Providence, Rhode Island, United States
J Int AIDS Soc 15:17701. 2012..4) of sequences, respectively. Conclusions: Prevalence of transmitted K65R and other tenofovir resistance mutations across diverse HIV-1 subtypes and recombinants is low, suggesting minimal effect on tenofovir-containing PrEP regimens... - Evolution of primary protease inhibitor resistance mutations during protease inhibitor salvage therapyRami Kantor
Division of Infectious Diseases and AIDS Research, Stanford University, Stanford, California 94301, USA
Antimicrob Agents Chemother 46:1086-92. 2002..The persistence of L90M, V82A/F/T, G48V, and I84V during salvage therapy suggests that these mutations play a role in clinical resistance to multiple PIs... - Discordances between interpretation algorithms for genotypic resistance to protease and reverse transcriptase inhibitors of human immunodeficiency virus are subtype dependentJoke Snoeck
Rega Institute for Medical Research, Minderbroedersstraat 10, 3000 Leuven, Belgium
Antimicrob Agents Chemother 50:694-701. 2006..It is not yet known whether therapy response is subtype dependent, but the advice given to clinicians based on a genotypic interpretation algorithm differs according to the subtype... - K103N mutation in antiretroviral therapy-naive African patients infected with HIV type 1Omobosola Akinsete
Department of Infectious Diseases, University of Minnesota Hennepin County Medical Center, Minneapolis, Minnesota 55455, USA
Clin Infect Dis 39:575-8. 2004.... - HIV type 1 genotypic variation in an antiretroviral treatment-naive population in southern IndiaPachamuthu Balakrishnan
YRG CARE, Centre for AIDS Research and Education, VHS, Taramani, Chennai 600 113, India
AIDS Res Hum Retroviruses 21:301-5. 2005..Larger scale studies need to be undertaken to better define the genotypic variation of circulating Indian subtype C viruses and their potential impact on drug susceptibility and clinical outcome in treated individuals... - A mutated CCR5 gene may have favorable prognostic implications in MSRami Kantor
Division of Infectious Diseases, Sheba Medical Center, Tel Hashomer, Israel
Neurology 61:238-40. 2003..Progression to disability was prolonged in Delta32CCR5 homozygotes and heterozygotes compared with MS patients with the CCR5 wild-type genotype (p < 0.005). Mutated CCR5 allele may be considered a favorable prognostic factor in MS...